SLS
SLS
NASDAQ · Biotechnology

Sellas Life Sciences Group I

$4.93
-0.02 (-0.40%)
As of May 9, 1:47 AM ET ·
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +587.6% upside
Low Target $25.20
Average Target $33.90
High Target $43.49
Current Price $4.93
Current
$4.93
Target
$33.90
$25.20 $33.90 avg $43.49
Scenario Analysis
Bear Case
$25.20
411.2%
Low target
Base Case
$33.90
+587.6%
Avg target
Bull Case
$43.49
+782.2%
High target
Risk/Reward
1.9x
Balanced
Price in Context
52-Week High
$6.14
-19.7% from high
52-Week Low
$1.36
+262.5% from low
Target vs 52W High
$33.90
+452.1% vs high
Next Earnings Report
May 11, 2026
Today
EPS Est: $-0.04
Earnings in today. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 75% $257.58 +27.8%
AMGN
Amgen Inc
Hold 44 48% $190.87 -42.5%
GILD
Gilead Sciences Inc
Strong Buy 39 79% $362.68 +176.2%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 +2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 38 79% $76.80 -89.3%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -65.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -19.5%
INSM
Insmed Inc
Strong Buy 28 96% $143.40 +41.5%